Personalized immune cells tested to fight five tough cancers
NCT ID NCT06626256
Summary
This early-stage study aimed to test the safety and early effectiveness of a personalized cell therapy called STIL101. The therapy involved growing a patient's own cancer-fighting immune cells (T-cells) from a tumor sample in a lab and then infusing them back. It was designed for adults with advanced, hard-to-treat forms of pancreatic, colorectal, kidney, cervical cancer, or melanoma who had already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.